FDA nod for Lupin's generic ulcer drug
28 August 2015 | News | By BioSpectrum Bureau
FDA nod for Lupin's generic ulcer drug
The capsules are generic version of AstraZeneca's Prilosec Delayed-Release capsules 40mg
Pharma Major Lupin Limited (Lupin) has announced that it has received final approval for its Omeprazole Delayed-Release capsules 40 mg from the United States Food and Drugs Administration (US FDA). The drug is a generic version of AstraZeneca Pharmaceuticals LP (AstraZeneca) Prilosec Delayed-Release capsules 40mg.
Lupin's Omeprazole Delayed-Release capsules 40 mg are the AB rated generic equivalent of AstraZeneca's Prilosec Delayed-Release capsules 40mg.
It is indicated for the short-term treatment of Duodenal Ulcer, Gastric Ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), maintenance of healing of Erosive Esophagitis and Pathological Hypersecretory conditions.
